MDR1 gene expression in solid tumours

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 1039-1050

  Goldstein, L J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CEFOPERAZONE; CYCLOSPORIN; CYTOTOXIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DILTIAZEM; DIPYRIDAMOLE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; EPIRUBICIN; ETOPOSIDE; GENE PRODUCT; GLYCOPROTEIN P; MESSENGER RNA; MITOMYCIN C; MITOXANTRONE; NIFEDIPINE; PROGESTERONE; QUINIDINE; QUININE; RESERPINE; TAMOXIFEN; TAXANE DERIVATIVE; TRIFLUOPERAZINE; UNINDEXED DRUG; VERAPAMIL; VINCA ALKALOID; VINCRISTINE;

BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG TRANSPORT; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SOLID TUMOR;

BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION; GENITAL NEOPLASMS, FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; UROGENITAL NEOPLASMS;

EID: 0030003252     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00100-1     Document Type: Article

References (84)

1. Biedler JL, Riehn H. Cellular resistance to actinomycin D in Chinese hamster ovary cells in vitro: cross resistance, radiographic and cytogenetic studies. Cancer Res 1970, 30, 1174-1184.
2. Croop JM, Gros P, Housman DE. Genetics of multidrug resistance. J Clin Invest 1988, 81, 1303-1309.
3. Endicott J, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989, 58, 137-171.
4. Kane SE, Pastan I, Gottesman MM. Genetic basis of multidrug resistance of tumor cells. Bioenergetics Biomembranes 1990, 22, 593-617.
5. Cornwall MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987, 262, 2166-2170.
6. Fojo AT, Akiyama SI, Gottesman MM, Pastan I. Reduced drug accumulation in multiple drug-resistant human KB carcinoma cell lines. Cancer Res 1985, 45, 3002-3007.
7. Tsuruo T, Iida H, Tsukagosti S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41, 1967-1972.
8. Chaudry PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66, 85-94.
9. Michetner EB, Roninson IB. Efficient inhibition of P-glycoprotein mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992, 89, 5824-5828.
10. Benson ML, Giella J, Whang IS, et al. Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder: implication and application. J Urol 1991, 146, 982-987.
11. Broxterman HJ, Feller N, Kuiper CM, et al. Correlation between functional and molecular analysis of mdr1 P-glycoprotein in solid-tumor xenografts. Im J Cancer 1995, 61, 880-886.
12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein, P170: evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein. Proc Natl Acad Sci USA 1987, 84, 7735-7738.
13. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (p-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86, 695-698.
14. Sugawara I, Kataoka I, Morischita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res 1988, 48, 4611-4614.
15. Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
16. Schinkel AH, Mol CAAM, Wagenaar E, et al. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995, 31A, 1295-1298.
17. Smit JJM, Schinkel AL, Oude Elferink RPJ, et al. Homozygous disruption of the murine mdr2 P-glycoprotein leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75, 451-462.
18. Borst P, Schinkel AH, Baas F, et al. Physiological functions of proteins involved in MDR. Anti-cancer Drugs 1994, 5, 66.
19. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84, 265-269.
20. Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor expiants. J Natl Cancer Inst 1989, 81, 844-849.
21. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 81, 116-124.
22. Kakehi Y, Kanamaru H, Yoshida O, et al. Measurement of multidrug resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 1988, 139, 862-865.
23. Mickley F, Fojo AT. In situ detection of MDR1 RNA in normal human tissues. Proc Am Assoc Cancer Res 1988, 29, 297.
24. Goldstein LJ, Fojo A, Ueda K, et al. Expression of the multidrug-resistance (MDR1) gene in neuroblastoma. J Clin Oncol 1989, 8, 128-136.
25. Bourhis J, BaAinard J, Hartmann O, Baccon-Gibod L, Lemerle J, Riou G. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 1989, 81, 1401-1405.
26. Ma DD, Davey RA, Harman DA, et al. Detection of a multidrug resistant phenotype in acute nonlymphoblastic leukemia. Lancet 1987, 1, 135-137.
27. Rothenberg ML, Mickley LA, Cole DE, et al. Expression of the mdr-1/P170 gene in patients with acute lymphoblastic leukemia. Blood 1989, 74, 1388-1395.
28. Sato H, Gottesman MM, Goldstein LJ, et al. Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Res 1990, 14, 11-22.
29. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991, 83, 708-712.
30. Chan HSL, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990, 8, 689-704.
31. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblas-toma. N Engl J Med 1991, 325, 1608-1614.
32. Lai SL, Goldstein LJ, Gottesman MM, et al. MDR1 expression in lung cancer. J Natl Cancer Inst 1989, 81, 1144-1150.
33. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, BaAinard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 1989, 49, 5062-5065.
34. Dalton WS, Grogan TM, Meltzer PS, et al. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989, 7, 415-424.
35. Moscow JA, Fairchild CR, Madden MJ, et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989, 49, 1422-1428.
36. ACS Cancer Facts Figures. American Cancer Society, 1994.
37. Ro J, Sahin A, Ro JY, Fritsche J, Hortobagyi G, Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990, 21, 787-791.
38. Gerlach JH, Bell DR, Kavabouser C, et al. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987, 5, 1452-1460.
39. Wallner J, Depisch D, Hopfner M, et al. MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 1991, 27, 1352-1355.
40. Verrelle P, Meissonnier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991, 83, 111-116.
41. Keith WN, Stallard S, Brown R. Expression of mdr1 and gst II in human breast tumors: comparison to in vitro chemosensitivity. Br J Cancer 1990, 61, 712-761.
42. Merkel DE, Fugua SAW, Tandona AK, Hill SM, Buzdar AV, McGuire WL. Electrophoretic analysis of 248 clinical breast specimens for p-GP overexpression or gene amplification. J Clin Oncol 1989, 7, 1129-1136.
43. Sanfillippo O, Ronchi E, DeMarco C, DiFronzo G, Silvestrini R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to Doxorubicin and vincristine. Eur J Cancer 1991, 27, 155.
44. Wishart GC, Plumb JA, Going JJ, et al. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990, 62, 758-761.
45. Schneider J, Bak M, Efferth TH, Kaufman M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989, 60, 815-818.
46. Uziely B, Delaflor-Weiss E, Lenz HJ, et al. Paclitaxel in refractory breast cancer: response correlates with low levels of MDR1 gene expression [Abstract]. Proc Am Soc Clin Oncol 1994, 13, 75.
47. Schneider J, Rubio M-P, Barbazan M-J, et al. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994, 86, 850-855.
48. Schneider J, Romero H. Correlation of P-glycoprotein over-expression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients. Anti-cancer Res 1995, 15, 1117-1122.
49. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
50. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992, 84, 1458-1460.
51. Cordon-Cardo C, O'Brien JP. The multidrug resistance phenotype in human cancer. Imp Adv Oncol 1991, 19-38.
52. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993, 85, 388-394.
53. Kirschling RJ, Jung SH, Jett JR. A phase II trial of Taxol and G-CSF in previously untreated patients with extensive stage small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 1994, 13, 326.
54. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993, 85, 384-388.
55. Langer CJ, Leighton JC, Comis, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a Phase II toxicity, response and survival analysis. J Clin Oncol 1995, 13, 1860-1870.
56. Young RC, Perez CA, Hoskins WJ. Cancer of the ovary. In DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott, 1993, 1226-1263.
57. Conte PF, Bruzzone M, Chiara S. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986, 4, 965-971.
58. Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 1985, 3, 311-315.
59. Riou GF, Zhou D, Ahomadegbe J, Gabillot M, Dunillard P, Lhomme C. Expression of multidrug-resistance (MDR1) gene in normal epithelia and in invasive carcinomas of the uterine cervix. J Natl Cancer Inst 1990, 82, 1493-1496.
60. Schneider J, Efferth T, Mattern J, Rodriguez-Escudero FJ, Volm M. Immunohistochemical detection of the multi-drug-resistance marker P-glycoprotein in uterine cervical carcinomas and normal cervical tissue. Am J Obstet Gynecol 1992, 166, 825-829.
61. Schneider J, Efferth T, Centeno J, Mattern J, Rodriquez-Escudero FJ, Volm M. High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue. Eur J Cancer 1993, 29A, 554-558.
62. Yamauchi M, Kumazawa H, Salta T, et al. Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining. Eur J Cancer 1992, 28A, 1422-1425.
63. Peters WHM, Boon CEW, Roelofs HMJ, Wobbes T, Nagengast FM, Kremers PG. Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology 1992, 103, 488-455.
64. Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991, 51, 2720-2726.
65. Sinicrope FA, Hart J, Brasitus TA, et al. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy and disease relapse. Cancer 1994, 74, 2908-2917.
66. Mayer A, Takimoto M, Fritz E, et at. The prognostic significance of proliferation cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71, 2454-2460.
67. Pirker R, Wallner J, Gsur A, et al. MDR1 gene expression in primary colorectal carcinomas. Br J Cancer 1993, 68, 691-694.
68. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992, 255, 459-462.
69. Huang C, Wu M, Xu G, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992, 84, 262-264.
70. Isshiki K, Nakao A, Ito M, Hamaguchi M, Takagi H. P-glycoprotein expression in hepatocellular carcinoma. J Surg Oncol 1993, 52, 21-25.
71. Itsubo M, Ishikawa T, Toda G, Tanaka M. Immunohistochemical study of expression and cellular localisation of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 1994, 73, 298-303.
72. Rochlitz C, Lobeck H, Peter S, et al. Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype. Cancer 1992, 69, 2993-2998.
73. Bak M, Efferth T, Mickisch G, Mattem J, Volm M. Detection of drug resistance and P-glycoprotein expression in human renal cell carcinomas. Eur Urol 1990, 17, 72-75.
74. Nishiyama K, Shirihama T, Yoshimura A, et al. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer 1993, 71, 3611-3619.
75. Volm M, Kastel M, Mattern J, Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-P, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993, 71, 3981-3987.
76. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice that express the human multidrug resistance gene in bone marrow enable a rapid identification of agents which reverse drug resistance. Proc Natl Acad Sci USA 1991, 88, 547-551.
77. Volm M, Pommerenke EW, Efferth T, Lohrke H, Mattern J. Circumvention of multidrug resistance in human kidney and kidney carcinoma in vitro. Cancer 1991, 67, 2484-2489.
78. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hor7 mone-refractory prostate cancer. J Clin Oncol 1992, 10, 1754-1761.
79. Hudes G, Obasaju C, McAleer C, et al. Phase I pharmacologic study of 96 hour infusional taxol combined with estramustine. Proc Am Soc Clin Oncol 1994, 13, 168.
80. Theyer G, Schirmbock M, Thaihammer T, Sherwood E, Baumgartner G, Hamilton G. Role of the MDR1 encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 1993, 150, 1544-1547.
81. Siegesmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman M. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 1994, 151, 45-491.
82. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med 1995, 333, 1380-1385.
83. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992, 112, 981-986.
84. Henson JW, Cordon-Cardo C, Posner JB. P-glycoprotein expression in brain tumors. JNeurooncol 1992, 14, 37-43.